Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γσ T cells
Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, Kabelitz D, Wesch D (2009)
Publication Type: Journal article
Publication year: 2009
Journal
Book Volume: 69
Pages Range: 8710-8717
Journal Issue: 22
DOI: 10.1158/0008-5472.CAN-09-1602
Abstract
Toll-like receptor (TLR) agonists are considered adjuvants in clinical trials of cancer immunotherapy. Here, we investigated the modulation of γδ T cell-mediated tumor cell lysis by TLR ligands. γδ T-cell cytotoxicity and granzyme A/B production were enhanced after pretreatment of tumor cells with TLR3 [poly(I:C)] or TLR7 ligand (imiquimod). We examined TLR3- and TLR7-expressing pancreatic adenocarcinomas, squamous cell carcinomas of head and neck and lung carcinomas. Poly(I:C) treatment of pancreatic adenocarcinomas followed by coculture with γδ T cells resulted in an upregulation of CD54 on the tumor cells. The interaction of CD54 and the corresponding ligand CD11a/CD18 expressed on γδ T cells is responsible for triggering effector function in γδ T cells. Moreover, treatment with imiquimod downregulated MHC class I molecules on tumor cells possibly resulting in a reduced binding affinity for inhibitory receptor NKG2A expressed on γδ T cells. These results indicate that TLR3 or TLR7 ligand stimulation of tumor cells enhances the cytotoxic activity of expanded γδ T cells of cancer patients in vitro. ©2009 American Association for Cancer Research.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Shojaei, H., Oberg, H.-H., Juricke, M., Marischen, L., Kunz, M., Mundhenke, C.,... Wesch, D. (2009). Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γσ T cells. Cancer Research, 69(22), 8710-8717. https://doi.org/10.1158/0008-5472.CAN-09-1602
MLA:
Shojaei, Harried, et al. "Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γσ T cells." Cancer Research 69.22 (2009): 8710-8717.
BibTeX: Download